Relevant Studies & Resources For those interested in learning more about the research behind IGF-1, IGFBP-3, and their connection to cancer risk and hormone signaling, here are several peer-reviewed studies and academic resources: Circulating Growth Factor Concentrations and Breast Cancer Risk: A Nested Case-Control Study of IGF-1, IGFBP-3, and Breast Cancer in a Family-Based Cohort PMC Insulin-like Growth Factor (IGF)-I, IGF Binding Protein-3, and Cancer Risk: Systematic Review and Meta-Regression Analysis PubMed The Expression and Function of IGFBP-3 in Normal and Malignant Breast Tissue Anticancer Research IGF-1, IGFBP-3, and Cancer Risk The Lancet Concentrations of IGF-I and IGFBP-3 and Pancreatic Cancer Risk in the European Prospective Investigation into Cancer and Nutrition British Journal of Cancer Genetic Polymorphisms in the IGFBP3 Gene: Association with Breast Cancer Risk and Blood IGFBP-3 Protein Levels Among Chinese Women Cancer Epidemiology, Biomarkers & Prevention Plasma Levels of Insulin-Like Growth Factor-I and Lung Cancer Risk: A Case-Control Analysis Journal of the National Cancer Institute Alterations of Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) Glycosylation in Patients with Breast Tumours Clinical Biochemistry
Figure 3 6 Conclusion In summary, tirzepatide, a dual agonist of the GLP-1 and GIP receptors, shows promising potential for the management of obesity-related OSAS by promoting weight loss, improving metabolic function, and modulating inflammatory pathways
The AE-QoL questionnaire [1] was specifically developed for angioedema patients and explores four different domains: food, fatigue/mood, fear/shame, and functioning
#weightloss #glp1 #weightlosstips #glp1patch #weightlosspatch | Dr White Talks About
E., Kitch, D
Vascular adaptation
